Metrics as of 10/14/2026, 08:30 AM (Berlin time), refresh in progress.
Immix Biopharma Stock
Immix Biopharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ilya Rachman
- Employees
- 21
- Market cap
- $473 M
- IPO
- 16/12/2021
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing…
Immix Biopharma stock: price history
1D
-6.1%
1W
-9.9%
1M
-28.4%
6M
-11.8%
YTD
+66.2%
1Y
+247.6%
2Y
+499.3%
5Y
–
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~10% weaker price swings than usual
Immix Biopharma stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 22/09/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Immix Biopharma is a clinical-stage biopharmaceutical company focused on developing therapy-specific treatments. Research priorities are primarily in oncology and inflammatory diseases such as ulcerative colitis and Crohn's disease. The portfolio comprises various biologic drugs (such as IMX-110, IMX-111, and IMX-120) currently undergoing clinical trials. Through strategic partnerships with companies like BeiGene Ltd., research into combination therapies for treating solid tumors is being advanced. Business operations are distributed across the United States and Australia.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Weak
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Immix Biopharma
Analyst assessment of Immix Biopharma
PRICE TARGET LOW
US$19.00
CONSENSUS
US$23.33
MEDIAN
US$25.00
PRICE TARGET HIGH
US$26.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 29/09/2026
Immix Biopharma stock metrics
P/E
-9.88
P/B
2.42
EV/EBITDA
-6.19
RETURN ON EQUITY
-5.0%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.8%
FLOAT SHARES
43,398,554
AVG. DAILY VOLUME (30D)
1,618,616
Insider transactions (SEC)
Hsu Jason
BUCHAN JANE
Chudnovsky Yekaterina
CHANG NANCY T
Marquet Magda
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Immix Biopharma stock
What does Immix Biopharma do?
Immix Biopharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ilya Rachman, the company employs around 21 people.
The IPO was on 16/12/2021; the stock trades on NASDAQ under the ticker IMMX.
What do analysts say about Immix Biopharma stock?
6 analysts rate the stock, the consensus is Buy (as of 29/09/2026).
The average price target is US$23.33, ranging from US$19.00 to US$26.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Immix Biopharma report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly -10% stronger than usual.
Does Immix Biopharma pay a dividend?
No, Immix Biopharma currently does not pay a dividend.
Which stocks are comparable to Immix Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Immix Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immix Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.